Connecting cutting-edge cancer research and oncology education
3nodes
Prague, Brno, Olomouc
5
research programmes
11
research institutes
71
research teams
1shared goal
progress in the fight against cancer
News and announcements
16. 4. 2024
Second patient conference focused on hormone-dependent cancers, such as breast or prostate cancer.
12. 4. 2024
Medical Tribune, 12 April 2024
Jiří Neužil's team at the Prague node had synthesised a mitochondria-targeting TPP+-labeled tamoxifen, so far the only drug of this kind in clinical research worldwide.
Jiří Neužil's team at the Prague node had synthesised a mitochondria-targeting TPP+-labeled tamoxifen, so far the only drug of this kind in clinical research worldwide.
Key persons
Prof. MUDr. Aleksi Šedo, DrSc.
Principal investigator of the project and Director of the National Institute for Cancer Research
Head of the Prague node
Head of research programme Molecular Foundation of Cancers and Molecular Goals
Head of research programme Molecular Foundation of Cancers and Molecular Goals
Prof. RNDr. Ondřej Slabý, Ph.D.
Scientific Director of the National Institute for Cancer Research
Head of the Brno node
Head of research programme Biomarkers of Cancers and Diagnostics of Cancers
Home institution: Faculty of Medicine and Central European Institute of Technology (CEITEC) of the Masaryk University
Doc. MUDr. Marián Hajdúch, Ph.D.
Medical Director of the National Institute for Cancer Research
Head of the Olomouc node
Head of the research programme Research and development of anticancer pharmaceuticals and therapeutic methods
Home institution: Faculty of Medicine of Palacký University